Industry news

Baxalta commences business

Read time: 1 mins

Last updated:1st Jul 2015

Published:1st Jul 2015

Source: Pharmawand

Baxalta, spun out of Baxter, launches on 1 July 2015 to develop and promote products in haematology, immunology and to expand its oncology business. Prime products for haematology include Advate, Bebulin, Feiba, Hemofilm, Obizumab, Recombinate and Rixubis. Products for Immunology are Gammagard Liquid, Gammagard S/D and Hyqvia. Products for Pulmonology are Araplast NP and Glassia. Products for Critical Care are Buminate, Flexbumin and Ceprotin. And for oncology, Oncaspar.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Xoma Corporation announces completion of acquisition of shares of Kinnate Biopharma Inc.

XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health

1 mins

Industry news

Regeneron Pharma and Mammoth Biosciences collaborate on CRISPR based gene editing therapies.

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types

1 min

Industry news

Antibe Therapeutics has receiver appointed.

Antibe Therapeutics Inc. announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) was heard before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, 2024 and the decision was reserved

1 min

See all news